Skip to content
Biodatica
Start free

Investigator

Yong Teng

EMORY UNIVERSITY · funded by NIDCR

Companies
1

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$1.1M

Summed across those awards.

First award
Feb 15, 2024

Latest Mar 1, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer

    $379k

    Mar 1, 2024NIDCREMORY UNIVERSITYNIH RePORTER · 11042236 (opens the source filing in a new tab)

  2. R01

    Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer

    $386k

    Mar 1, 2024NIDCREMORY UNIVERSITYNIH RePORTER · 11322613 (opens the source filing in a new tab)

  3. R01

    Targeted Arf1 inhibition to enhance immune response in oral cancer

    $372k

    Feb 15, 2024NIDCREMORY UNIVERSITYNIH RePORTER · 11249643 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources